DelveInsight’s, “Relapsed/refractory Acute Myeloid Leukemia Pipeline Insight, 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/refractory acute myeloid leukemia pipeline drug profiles, including Relapsed/refractory acute myeloid leukemia clinical trials and nonclinical stage products. It also covers the Relapsed/refractory acute myeloid leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Relapsed/Refractory Acute Myeloid Leukemia pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Relapsed/Refractory Acute Myeloid Leukemia NDA approvals (if any), and product development activities comprising the technology, Relapsed/refractory acute myeloid leukemia (AML) collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
Key takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
To explore more information on the latest breakthroughs in the Relapsed/Refractory Acute Myeloid Leukemia Pipeline treatment landscape of the report, click here @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook
Relapsed/Refractory Acute Myeloid Leukemia Overview
Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. The prognosis of relapsed acute myeloid leukemia (AML) is poor and treatment is challenging. The signs and symptoms of acute myeloid leukemia (AML) are common to other, less serious illnesses. It is common for people with AML to feel a loss of well-being because of the underproduction of normal bone marrow cells. Symptoms of a low red blood cell count (called “anemia”) include: Fatigue, weakness, shortness of breath during normal physical activities, lightheadedness, dizziness or faintness, headaches and pale complexion. Other general symptoms of AML include: Loss of appetite, unexplained weight loss, discomfort in bones or joints, fullness or swelling in the abdomen, due to an enlarged spleen or liver.
Recent Development Activities in the Relapsed/Refractory Acute Myeloid Leukemia Treatment Landscape
Request a sample and discover the recent advances in Relapsed/Refractory Acute Myeloid Leukemia Ongoing Clinical Trial Analysis and Medications, click here @ Relapsed/Refractory Acute Myeloid Leukemia Treatment Landscape
Relapsed/refractory acute myeloid leukemia (AML) Emerging Drugs Profile
APG-2575: Ascentage Pharma
APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).
CLN 049: Cullinan Oncology
CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.
Lanraplenib: Kronos Bio
Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Relapsed/refractory acute myeloid leukemia (AML). The companies which have their Relapsed/refractory acute myeloid leukemia (AML) drug candidates in the most advanced stage, i.e. Phase I/II include, Ascentage Pharma.
For further information, refer to the detailed Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs, Relapsed/Refractory Acute Myeloid Leukemia Market Drivers, and Market Barriers, click here for Relapsed/Refractory Acute Myeloid Leukemia Ongoing Clinical Trial Analysis
Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
Dive deep into rich insights for drugs for Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Relapsed/Refractory Acute Myeloid Leukemia Market Barriers, click here @ Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Relapsed/refractory acute myeloid leukemia Mergers and acquisitions, Relapsed/refractory acute myeloid leukemia licensing activities @ Relapsed/refractory acute myeloid leukemia Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services